Robert Carlson is a Rare Disease Specialist at Arrowhead Pharmaceuticals, focusing on strategic readiness for the launch of an investigational siRNA therapy targeting APOC3 for treating Familial Chylomicronemia Syndrome and Severe Hypertriglyceridemia. Previously, Robert served as a Regional Business Leader at Lexicon Pharmaceuticals, where leadership of a cross-functional team facilitated the launch of a first-in-class SGLT inhibitor for heart failure across multiple states. As an Area Business Leader at Sanofi, Robert drove sales and account strategy for MULTAQ in the Atrial Fibrillation area, enhancing access within complex treatment pathways. Earlier experiences include leading a high-performing commercial team at Kowa Pharmaceuticals and achieving national recognition at Reliant Pharmaceuticals for exceptional sales results and leadership. Robert holds a B.A. in Economics from Indiana University Bloomington and Wright State University.
This person is not in any teams
This person is not in any offices